Know Cancer

or
forgot password

A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Small Cell Lung Carcinoma

Thank you

Trial Information

A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Cancer


The study prematurely discontinued on January 26, 2011 due to slow enrollment. It should be
noted that safety concerns have not been seen in this study and have not factored into this
decision.


Inclusion Criteria:



- Histologically confirmed diagnosis of extensive stage disease Small Cell Lung Cancer
(SCLC), with tumor biopsy sample required.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Total IGF-1 > or
= 120 ng/ml

Exclusion Criteria:

- Any prior systemic therapy for Small Cell Lung Cancer (SCLC)

- HbA1c > or = 5.7%

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-Free Survival (PFS)

Outcome Description:

Median time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS time (days) = [event (progression or death) date or censor date - date of randomization + 1].

Outcome Time Frame:

Baseline, every 2nd cycle (between Day 15-21, 1 cycle = 21 days) starting with Cycle 2 until disease progression, at the end of treatment visit (if more than 28 days have passed since last evaluation); and every 6 weeks until disease progression

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4021032

NCT ID:

NCT00977561

Start Date:

April 2010

Completion Date:

October 2011

Related Keywords:

  • Small Cell Lung Carcinoma
  • Small Cell Lung Cancer
  • Extensive stage disease
  • SCLC
  • IGF-1R inhibitor
  • Carcinoma
  • Lung Neoplasms
  • Small Cell Lung Carcinoma

Name

Location

Pfizer Investigational Site Richmond, Virginia  23249
Pfizer Investigational Site Federal Way, Washington  98003
Pfizer Investigational Site Columbia, Missouri  65201
Pfizer Investigational Site Asheville, North Carolina  28801
Pfizer Investigational Site Eugene, Oregon  97401
Pfizer Investigational Site Kingston, Pennsylvania  18704-5535
Pfizer Investigational Site Shreveport, Louisiana  71103
Pfizer Investigational Site Livingston, New Jersey  07039
Pfizer Investigational Site Washington, District of Columbia  20007-2197